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Abstract
Purpose: 18F-ﬂuorodeoxyglucose (FDG) positron emission tomographye(PET)/computed
tomography (CT) imaging is used for staging and treatment planning of patients with anal cancer.
Quantitative pre- and posttreatment metrics that are predictive of recurrence are unknown. We
evaluated the association between pre- and posttreatment FDG-PET/CT parameters and outcomes
for patients with squamous cell carcinoma of the anus (SCCA).
Methods and materials: The records of 110 patients treated between 2003 and 2013 with deﬁn-
itive radiation therapy for SCCA were reviewed under an institutional review boardeapproved
protocol. The median radiation therapy dose was 50.4 Gy (range, 35-60 Gy). Concurrent
chemotherapy was administered for 109 of 110 patients and generally consisted of 5-ﬂuorouracil
and mitomycin C (n Z 94). All patients underwent pretreatment FDG-PET/CT and 101 of 110
underwent posttreatment FDG-PET/CT 3 months after completion of radiation therapy. The
maximum standard uptake value (SUVmax) was analyzed, in addition to multiple patient and
treatment factors, by univariate and multivariate Cox regression for correlation with local
recurrence (LR) and overall survival (OS).
Results: The median follow-up was 28.6 months. LR occurred in 1 of 15 (6.7%), 5 of 47 (10.6%),
and 6 of 48 (12.5%) patients with stage I, II, and III disease, respectively. On univariate analysis, a
signiﬁcant association was observed between reduced LR and posttreatment SUVmax <6.1 (P Z
.0095) and between increased OS and posttreatment SUVmax <6.1 (P Z .0086). On multivariate
analysis, a signiﬁcant association was observed between reduced LR and posttreatment SUVmax
<6.1 (P Z .0013) and the use of intensity modulated radiation therapy (P < .001). A
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signiﬁcant multivariate association was observed between increased OS and posttreatment SUVmax
<6.1 (P Z .0373) and the use of 5-ﬂuorouracil/mitomycin C chemotherapy (P Z .001).
Conclusion: Posttreatment SUVmax <6.1 is associated with reduced LR and increased OS after
chemoradiation therapy for SCCA independent of T and N stage on multivariate analysis. Greater
follow-up is required to conﬁrm this association with late patterns of failure.
ª 2017 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Anal cancer is a rare malignancy of the gastrointestinal
tract with an annual incidence of 2.04 to 2.06 per 100,000
in the United States for men and women, respectively.1
Squamous cell carcinoma of the anus (SCCA) accounts
for approximately 90% of primary anal malignancies.2
Known risk factors for SCCA are HIV and human pap-
illoma virus infections, immunodeﬁciency, and smoking.
The combination of chemotherapy, consisting of
5-ﬂuorouracil (5-FU) and mitomycin-C (MMC), and ra-
diation has emerged as the standard of care for SCCA,
with surgery reserved for salvage therapy.3-8 Radiation
Therapy Oncology Group (RTOG) 0529 was a phase
2 trial that showed a signiﬁcant reduction in grade 2þ
hematological and grade 3þ gastrointestinal toxicities
with the use of a dose-painted intensity modulated radi-
ation therapy (DP-IMRT) regimen compared with the
conventional regimen used in RTOG 9811.9 The reduced
toxicity observed in RTOG 0529 has led to the adoption
of IMRT as the standard of care.10
Previous studies have shown that T and N stages are
prognostic factors that are correlated with overall and
disease-free survival and that risk of nodal disease is
directly associated with more advanced T stage.11
Furthermore, most treatment failures occur at the pri-
mary tumor site, followed by regional nodal failure.12,13
The role of 18F-ﬂuorodeoxyglucose (FDG)epositron
emission tomography (PET)/computed tomography (CT)
in the staging of SCCA has been evaluated by numerous
studies. FDG-PET/CT has been shown to be a more
sensitive imaging modality for detecting primary and
nodal disease compared with CT.14,15 In one study, FDG-
PET/CT upstaged disease in 14% of cases and changed
treatment planning in 17%.16 A previous report detailed
the qualitative metabolic response on posttreatment FDG-
PET/CT and the association with cause-speciﬁc survival
(CSS) and progression-free survival (PFS).17 The goals of
this study were to evaluate the correlation of quantitative
measures of FDG-PET/CT and IMRT treatment with
local recurrence (LR) and overall survival (OS) and to
compare recurrence outcomes both for quantitative
measures and qualitative interpretation of the scans.
Methods and materials
Patients
In an institutional review boardeapproved study at
Washington University in St. Louis, MO, the clinical
records and PET/CT scans of patients who were treated
with deﬁnitive radiation therapy for SCCA from 2003 to
2013 were retrospectively reviewed.
Clinical staging
Staging consisted of history and physical examination,
digital rectal examination, anoscopy, and whole body
FDG-PET/CT scans with a biopsy of the primary lesion
and biopsy or ﬁne-needle aspiration of the suspicious
lymph nodes when clinically indicated.
Treatment
The method of radiation therapy delivery for SCCA
transitioned from a 3-dimensional chemoradiotherapy
(CRT) approach to IMRT during the course of the study
period. Of the 110 patients in the study, 28 were treated
conventionally and 82 with IMRT. Conventional treatment
consisted of a 4-ﬁeld box beam arrangement to the pelvis
and photon and/or electron ﬁelds to the groin. To reduce
the dose to the small bowel, femoral heads, bladder, iliac
crest, large bowel, and external genitalia, IMRT plans were
adopted. During the initial transition to IMRT, sequential
plans were used. Generally, 30 Gy was delivered at 2 Gy
per fraction for T1-2, T3, and T4 lesions. In the later years
of the study, boost doses were incorporated into DP-IMRT
fractions. With DP-IMRT, T2N0 disease was treated with
50.4 Gy and 42 Gy to the tumor and elective nodes,
respectively, in 28 fractions. T3-4N0-3 disease was treated
with 54 Gy to the tumor and 45, 50.4, and 54 Gy to the
elective nodal, nodal disease <3 cm, and nodal disease >3
cm, respectively, in 30 fractions.
A total of 94 patients received chemotherapy with
5-FU and MMC. This consisted of 2 cycles of 5-FU (1000
mg/m2/d as a 96-hour infusion on days 1-5 and days
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29-33 of DP-IMRT) and MMC (10 mg/m2 bolus on days
1 and 29). Eight patients received 5-FU only and 5 pa-
tients received 5-FU and cisplatin. One patient received
5-FU and octreotide and one received cisplatin and eto-
poside. Only one patient refused chemotherapy. A full list
of patient characteristics is given in Table 1.
Follow-up
Follow-up consisted of a physical and digital rectal
examination and an anoscopy at 3 months initially after
completion of treatment and then every 6 months for
5 years. Follow-up whole-body FDG-PET/CT was done
at a median of 3.8 months after completion of treatment.
Additional imaging was obtained annually or as clinically





FDG-PET/CT scans were performed on hybrid FDG-
PET/CT scanners (Biograph LSO 2, Biograph 40, Bio-
graph Duo, Biograph mCT, Siemens Medical Solutions,
Malvern, PA). CT scans were noncontrast images with
5-mm slices taken from the skull base through the
proximal thigh with x-ray beam attenuation settings at
130 peak kVp and 110 effective mAs. PET images
were taken at the same anatomical range and obtained
40 to 118 minutes after the administration of 11 to 20
mCi 18F (t1/2Z 109.8 minutes) with imaging times of 2 to
4 minutes per bed position, depending on patient weight.
Primary tumors were contoured and quantitative measures
of the region of interest (ROI) were taken using MIM-
Vista software (MIM Software Inc., Cleveland, OH). The
maximum standard uptake value (SUVmax) of the ROI
was used as the measure of avidity. Brieﬂy, SUV is the
ratio of the pixel intensity of the ROI divided by the
hypothetical value of intensity where the radiotracer is
distributed evenly throughout the body:
SUVðtÞZ tissue activityðtÞ
injected activityðtÞ=body mass
DSUVmax was deﬁned as the percentage change in
SUVmax from pretreatment to posttreatment FDG-PET/
CT. Radiology reports of the posttreatment FDG-PET/
CT scans were reviewed for qualitative data. On the
basis of the reports, patients were classiﬁed as having
complete response or incomplete response.
Statistical analysis
Survival was estimated using the Kaplan-Meier
method. Univariate and stepwise multivariate Cox pro-
portional hazard models were used to evaluate the asso-
ciation between variables of FDG-PET, radiation therapy
modality, chemotherapy, T stage, N stage, and HIV with
local recurrenceefree survival (LRFS) and OS. Chemo-
therapy was categorized as “5-FU/MMC” and “Other”
(including all other regimens). Cut-points were deter-
mined statistically for survival data using the outcome-
oriented cut-point methodology deﬁned by Contal and
O’Quigley.18
Qualitative and quantitative measures were compared
with the c2 and Fisher’s exact tests. The strength of as-
sociation was quantiﬁed with Cohen’s kappa coefﬁcient.
P < .05 was considered statistically signiﬁcant. All tests
were 2-sided. Statistical analyses were performed with
StatView and SAS (Versions 5.0.1 and 9.2, respectively;
SAS Institute Inc., Cary, NC).
Results
Patient factors
The records of 110 patients treated between 2003 and
2013 with deﬁnitive radiation therapy were reviewed. The
average age at diagnosis was 54.5 years. The number of
HIVþ patients was 31 (28.2%), of whom 25 were
managed with antiretroviral therapy. CD4þ T cell counts
were available at the time of treatment for 21 of these
patients (range, 8-1031). A total of 109 patients received
chemotherapy. A full list of patient characteristics is
shown in Table 1.
Table 1 Patient characteristics
Characteristic n (%)
Age
65 y 17 (15.4)

















5FU, 5-ﬂuorouracil; MMC, mitomycin C.
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Clinical outcomes
The median follow-up was 28.6 months (range,
3.6-94.1 months). There were 12 LRs and 24 deaths
among the 110 patients in the study. One of 15 patients
with stage I disease (6.7%), 5 of 47 patients with stage II
disease (10.6%), and 6 of 48 patients with stage III
disease (12.5%) had LR. Patients with and without LR





During pretreatment FDG-PET/CT, the mean SUVmax
was 11.73. Among patients with and without LR, the
mean pretreatment SUVmax was 9.97 and 11.95,
respectively. The median time to posttreatment FDG-
PET/CT was 3.8 months. Mean posttreatment SUVmax
was 4.73, and mean posttreatment SUVmax among pa-
tients with and without LR was 5.35 and 4.66,
respectively.
An SUVmax of 6.1 was identiﬁed as the appropriate
cut-point for survival analysis. Patients at or below this
cut-point on the basis of posttreatment imaging were
classiﬁed as SUVmax low and those above were classiﬁed
as SUVmax high. Similarly, a DSUVmax of 62.3% was
identiﬁed as the appropriate cut-point for survival
analysis.
During posttreatment FDG-PET/CT, 40 of 101 patients
were reported as having a complete response qualitatively
on the basis of a radiology review. All others were clas-
siﬁed as having incomplete response. Twenty-two of
twenty-six SUVmax high patients were classiﬁed as having
an incomplete response and 39 of 75 SUVmax low patients
were classiﬁed as having a complete response.
Radiation therapy technique
The radiation therapy technique was 3-dimensional
CRT for 28 patients and IMRT for 82 patients. The me-
dian follow-up for the 3-dimensional CRT group was 36
months versus 24 months for the IMRT group. The
3-dimensional CRT group had 8 LRs with a median time
to recurrence of 12 months versus 4 LRs in the IMRT
group, with a median time to recurrence of 20 months.
Two-year LRFS was 72% for the 3-dimensional CRT and
95% for the IMRT group (P < .01). Recurrence-free
survival was 86% for the IMRT group and 72% for the
3-dimensional CRT group at 2 years (P Z .09). OS was
88% for both groups at 2 years (P Z .4). Within the
IMRT group, there were 2 LRs each in the simultaneous
integrated boost and the sequential boost groups.
Univariate analysis
On univariate analysis of FDG-PET/CT factors, a
signiﬁcant association was observed between improved
LRFS and pretreatment SUVmax >7.1 (hazard ratio [HR]
Z 0.2788, PZ .0296) and between improved LRFS and
posttreatment SUVmax <6.1 (HRZ 0.2276, PZ .0172).
A signiﬁcant univariate association was also observed
between increased OS and posttreatment SUVmax <6.1
(HR Z 0.3050, P Z .0127). Kaplan-Meier curves for
posttreatment SUVmax groups for LRFS and OS are
shown in Figures 1A and B.
A DSUVmax of greater magnitude than 62.3% was
associated with improved OS (HRZ 0.2283, PZ .0080)
but was not a signiﬁcant predictor of LRFS on univariate
analysis.
On univariate analysis of clinical factors, no correla-
tion was found between HIV status and LR risk. The
correlation between T/N stage and LR risk approached
but did not reach a signiﬁcance in this data set.
On univariate analysis of treatment factors, a signiﬁ-
cant association was observed between improved LRFS
and the use of 5-FU/MMC chemotherapy (HRZ 0.2079,
P Z .0114). This chemotherapy regimen was also
signiﬁcantly associated with increased OS on univariate
analysis (HR Z 0.0811, P < .0001). Additionally, there
was a signiﬁcant association between improved LRFS and
the use of IMRT compared with conventional radiation
therapy (HR Z 0.1839, P Z .0058).
Multivariate analysis
On multivariate analysis, a signiﬁcant association was
observed between increased LRFS and posttreatment
SUVmax <6.1 (HRZ 0.1658, PZ .0013) and the use of
IMRT (HR Z 0.0930, P Z .0002). The variables of 5-
FU/MMC chemotherapy and pretreatment SUVmax >7.1
were not signiﬁcant for LR on multivariate analysis.
A signiﬁcant multivariate association was observed
between increased OS and posttreatment SUVmax <6.1
(HR Z 0.3551, P Z .0373). Similarly, a DSUVmax of
greater magnitude than 62.3% was associated with
increased OS (HR Z 0.3000, P Z .0298). 5-FU/MMC
chemotherapy was strongly associated with increased OS
(HR Z 0.1060, P < .0001).
Categorical analysis
On c2 analysis and Fisher’s exact test, there was a
signiﬁcant association between the qualitative and quan-
titative analyses of the FDG-PET/CT scan (P Z .0034
and P Z .0047, respectively) with a kappa value of
0.2265 (95% conﬁdence interval, 0.09-0.75), which
indicates a fair association.19 The qualitative assessment
did not reach signiﬁcance in predicting LR.
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Discussion
Most studies on the role of FDG-PET/CT in SCCA
have focused on the diagnostic and treatment planning
signiﬁcance of this imaging modality. There is only
limited literature on the independent and quantitative
prognostic signiﬁcance of FDG-PET/CT in SCCA. A
previous study of FDG-PET/CT in anal cancer correlated
metabolic response with patient outcomes. In the current
study, 53 patients with SCCA received chemoradiation
and had a staging FDG.
PET/CT and follow-up FDG-PET/CT occurred at a
mean of 2.1 months after completion of therapy. At
follow-up, patients were stratiﬁed as either having a
complete metabolic response (SUVmax in the ROI no
greater than blood pool SUV) or a partial response
(SUVmax in the ROI greater than blood pool SUV) as
judged by the radiologist. The endpoints of the study were
2-year CSS and 2-year PFS. Patients with a complete
metabolic response had a 2-year CSS and a 2-year PFS of
94% and 95%, respectively. Patients with a partial
metabolic response had 2-year CSS and 2-year PFS of
39% and 22%, respectively.17 To the authors’ knowledge,
our study is the ﬁrst to correlate the quantitative values of
SUVmax on pretreatment and posttreatment FDG-PET/CT
with LRFS.
Our results suggest that in SCCA, a higher posttreat-
ment SUVmax is predictive of worse clinical outcomes.
This ﬁnding is consistent with a previous qualitative study
that evaluated tumors as complete or partial responders.
We investigated the level of covariance between the
qualitative reports on the basis of initial radiology reports
Figure 1 (A) Kaplan Meier survival analysis of Post-treatment SUVmax groups and Local Recurrence Free Survival. The number of
patients at risk at the time of each local recurrence event is shown above the respective curves. (B) Kaplan Meier survival analysis of
Post-treatment SUVmax groups and Overall Survival. The number of patients at risk at the time of each mortality event is shown above
the respective curves.
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and the quantitative data in this study. As expected, there
is a signiﬁcant correlation; however, the strength of this
association was not robust. The majority of non-
responders on the basis of quantitative analysis (high
posttreatment SUVmax) were also categorized as incom-
plete responders qualitatively. However, the responders
on the basis of quantitative analysis (low posttreatment
SUVmax) were inconsistently classiﬁed as such qualita-
tively. Overall, two-thirds of posttreatment FDG-PET/CT
scans were read as incomplete response. This fact diluted
the data set such that qualitative assessment failed to reach
signiﬁcance in predicting LR. In this context, a quanti-
tative threshold for posttreatment tumor SUVmax may be
useful and potentially more speciﬁc for predicting LR.
The observation that higher SUVmax during pre-
treatment FDG-PET/CT was associated with better
clinical outcomes was unexpected and unusual. How-
ever, this ﬁnding was not signiﬁcant on multivariate
analysis and was likely due to a skewed number of pa-
tients in this group who did not receive 5-FU/MMC
chemotherapy.
There are a number of potential weaknesses in this
study. There is limited follow-up of patients at the later
time points. It is possible that some of these patients had
LR after the conclusion of the study period. This may
partially explain the improvement observed in LRFS with
the use of IMRT. Additionally, through the course of the
study multiple PET/CT scanners were used, and it is
possible that different scanners had variable quantiﬁca-
tions of FDG uptake.
FDG uptake has been shown to be predictive of out-
comes after treatment in a number of solid tumors and
lymphoma. Most reports show that greater PET avidity is
predictive of worse outcomes. Sakaki et al demonstrated
that SUVmax >5.0 was associated with worse OS and
disease-free survival in non-small cell lung cancer stages
I-IIIb.20 Pan et al conducted a systematic review of the
literature with regard to the prognostic signiﬁcance of
SUV in esophageal cancer. This group also found that a
high pretreatment SUV was predictive of worse OS and
disease-free survival.21
In lymphoma, PET avidity is positively correlated with
serum lactate dehydrogenase, which is a prognostic
marker, and more aggressive lymphomas typically have
high SUV values compared with indolent lymphomas.
FDG-PET/CT guide the management of lymphoma by
enabling assessment of response to treatment in the
posttreatment scenario and the identiﬁcation of refractory
disease during treatment.22
In work presented at the 2014 Annual Meeting of the
American Society for Radiation Oncology, Mai et al re-
ported a retrospective study of the inﬂuence of human
papilloma virus status and p16 expression on outcomes in
patients with anal cancer who were treated with chemo-
radiation therapy.23 Although this was not available for
the patients in our study, future studies can evaluate the
relationship between human papilloma virus infection
status and PET avidity in both pre- and posttreatment
scenarios.
Conclusion
Posttreatment SUVmax <6.1 is associated with
increased LRFS and increased OS after chemoradiation
therapy for SCCA independent of T and N stage on
multivariate analysis. Our data suggest that the quantita-
tive metric of SUVmax may be more speciﬁc for LR than a
qualitative assessment of FDG-PET/CT. Greater follow-
up is required to conﬁrm the association with late pat-
terns of failure.
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